Alterations of the p15, p16, and p18 genes in osteosarcoma

Cancer Genetics and Cytogenetics

Volumn 86, Issue 2, 1996, Pages 136-142

  Miller, C W ^a,c   Aslo, A ^a   Campbell, M J ^a   Kawamata, N ^a   Lampkin, B C ^b   Koeffler, H P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHROMOSOMAL LOCALIZATION; CHROMOSOME 15P; CHROMOSOME 16P; CHROMOSOME 18P; CHROMOSOME 9P; CHROMOSOME ANALYSIS; ENZYME ACTIVITY; GENE DELETION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; HUMAN TISSUE; MISSENSE MUTATION; NORMAL HUMAN; OSTEOSARCOMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0029918497     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/0165-4608(95)00216-2     Document Type: Article

References (57)

1. Masuda H, Miller C, Koeffler HP, Battifora H, Cline MJ (1987): Rearrangement of the p53 gene in human osteogenic sarcomas. Proc Natl Acad Sci USA 84:7716-7719.
2. Toguchida J, Yamaguchi T, Ritchie B, Beauchamp RL, Dayton SH, Herrera GE, Yamamuro T, Kotoura Y, Sasaki MS, Little JB (1992): Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 52:6194-6199.
3. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Dryja TP (1986): A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323:643-646.
4. Fung YK, Murphree AL, T'Ang A, Qian J, Hinrichs SH, Benedict WF (1987): Structural evidence for the authenticity of the human retinoblastoma gene. Science 236:1657-1661.
5. Wadayama B, Toguchida J, Shimizu T, Ishizaki K, Sasaki MS, Kotoura Y, Yamamuro T (1994): Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res 54:3042-3048.
6. Kern SE (1994): p53: Tumor suppression through control of the cell cycle. Gastroenterology 106:1708-1711.
7. Ewen ME (1994): The cell cycle and the retinoblastoma protein family. Cancer Metastasis Rev 13:45-66.
8. Hunter T (1993): Breaking the cycle. Cell 75:839-841.
9. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D (1993): p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704.
10. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ (1993): The p21 Cdk-interacting protein Cip1 is a potent inhibitor of Gl cyclin-dependent kinases. Cell 75:805-816.
11. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B (1993): WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
12. Jiang H, Fisher PB (1993): Use of a sensitive and efficient subtraction hybridization protocol for the identification of genes differentially regulated during the induction of differentiation in human melanoma cells. Mol Cell Differ 1:285-299.
13. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR (1994): Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 211:90-98.
14. Gu Y, Turck CW, Morgan DO (1993): Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366:707-710.
15. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A (1994): p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 8:9-22.
16. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J (1994): Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59-66.
17. Toyoshima H, Hunter T (1994): p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, related to p21. Cell 78:67-74.
18. Hengst L, Dulic V, Slingerland JM, Lees E, Reed SI (1994): A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc Natl Acad Sci USA 91:5291-5295.
19. Matsuoka S, Edward M, Bai C, Parker S, Zhang P, Baldini A, Harper JW, Elledge SJ (1995): p57KIP2, a structurally distinct member of the p21CIP1 Cdk-inhibitor family, is a candidate tumor suppressor gene. Genes Dev 9:650-662.
20. Hannon GJ, Beach D (1994): p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371:257-261.
21. Guan KL, Jenkins CW, Li Y, Nichols MA, Wu X, O'Keefe CL, Matera AG, Xiong Y (1994): Growth suppression by p18, a p16INK4/MTSq- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 8:2939-2952.
22. Serrano M, Hannon GJ, Beach D (1993): A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707.
23. Hirai H, Roussel MF, Kato J, Ashmun RA, Sherr CJ (1995): Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 15:2672-2681.
24. Ka Ming Chan F, Zhang J, Cheng L, Shapiro DN, Winoto A (1995): Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4. Mol Cell Biol 15:2682-2688.
25. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, yTavtigian SV, Stockert E, Day RS, Johnson BE, Skolnick MH (1994): A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440.
26. Shiohara M, el-Deiry WS, Wada M, Nakamura T, Takeuchi S, Yang R, Chen DL, Vogelstein B, Koeffler HP (1994): Absence of WAF1 mutations in a variety of human malignancies. Blood 84:3781-3784.
27. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA (1994): Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756.
28. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PAT, Ally DS, Sheahan MD, Clark CH, Tucker MA, Dracopoli NC (1994): Germline p16 mutations in familial melanoma. Nat Genet 8:15-21.
29. Kamb A, Shattuckeidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J, McClure M, Aitken JF, Anderson DE, Bergman W, Frants R, Goldgar DE, Green A, MacLennan R, Martin NG, Meyer LJ, Youl P, Zone JJ, Skolnick MH, Cannon-Albright LA (1994): Analysis of the p16 gene (cdkn2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8:22-26.
30. Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, Riet P, Blaugarund JE, Sidransky D (1994): Rates of p16(mts1) mutations in primary tumors with 9p loss. Science 265:415-416.
31. Ueki K, Rubio MP, Ramesh V, Correa KM, Rutter JL, von Deimling A, Buckler AJ, Gusella JF, Louis DN (1994): Mts1/cdkn2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. Hum Mol Genet 3:1841-1845.
32. Ogawa S, Hirano N, Sato N, Takahashi T, Hangaishi A, Tanaka K, Kurosawa M, Tanaka T, Mitani K, Yazaki Y, Hirai H (1994): Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias. Blood 84:2431-2435.
33. Spruck CH, Gonzalez-Zulueta M, Shibata A, Simoneau AR, Lin MF, Gonzalez F, Tsai YC, Jones PA (1994): p16 gene in uncultured tumours. Nature 3706:183-184.
34. Zhang SY, Klienszanto AJP, Sauter ER, Shafarenko M (1994): Higher frequency of alterations in the p16/cdkn2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 54:5050-5053.
35. INK4B) display frequent homozygous deletions in primary cells from T- but not B-cell lineage acute lymphoblastic leukemias. Blood 84:4038-4044.
36. Hatta Y, Hirama T, Miller CW, Yamada Y, Tomonaga M, Koeffler HP (1995): Homozygous deletions of the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia. Blood 85:2699-2704.
37. Jen J, Harper WJ, Bigner SH, Papadopoulos N, Markowitz S, Willson JKV, Kinzler KW, Vogelstein B (1994): Deletion of p15 and p16 in brain tumors. Cancer Res 54:6353-6358.
38. Schmidt EE, Ichimura K, Reifenberger G, Collins VP (1994): CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54:6321-6324.
39. Mori T, Miura K, Aoki T, Nishihira T, Mori S, Nakamura Y (1994): Frequent somatic mutation of the mts1/cdk4i (multiple tumor suppressor cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 54:3396-3397.
40. Hayashi N, Sugimoto Y, Tsuchiya E, Ogawa M, Nakamura Y (1994): Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK41 (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem Biophys Res Commun 202:1426-1430.
41. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo SY, Kern SE (1994): Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8:27-32.
42. Okamoto A, Hussain SP, Hagiwara K, Spillare EA, Rusin MR, Demetrick DJ, Serrano M, Hannon GJ, Shiseki M, Zariwala M, Harris CC (1995): Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res 55:1448-1451.
43. Miller CW, Simon KJ, Aslo A, Yokota J, Buys CHCM, Terada M, Koeffler HP (1992): P53 mutation in human lung tumors. Cancer Res 52:1095-1098.
44. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T (1994): Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 86:2766-2770.
45. Johnson KR, Nauseef WN, Care A, Wheelock MJ, Shane S, Hudson S, Koeffler HP, Selsted M, Miller C, Rovera G (1994): Characterization of cDNA clones for human myeloperoxidase: Predicted amino acid sequence and evidence for multiple RNA species. Nucleic Acids Res 15:2013-2028.
46. Fasman KH, Cuticchia AJ, Kingsbury DT (1994): The GDB human genome data base anno 1993. Nucleic Acids Res 22:3462-3469.
47. Scheffer H, Kruize YC, Osinga J, Kuiken G, Oosterhuis JW, Leeuw JA, Schraffordt Koops H, Buys CH (1991): Complete association of loss of heterozygosity of chromosomes 13 and 17 in osteosarcoma. Cancer Genet Cytogenet 53:45-55.
48. Yamaguchi T, Toguchida J, Yamamuro T, Kotoura Y, Takada N, Kawaguchi N, Kaneko Y, Nakamura Y, Sasaki MS, Ishizaki K (1992): Allelotype analysis in osteosarcomas: Frequent allele loss on 3q, 13q, 17p, and 18q. Cancer Res 52:2419-2423.
49. Romano JW, Ehrhart JC, Duthu A, Kim CM, Appella E, May P (1989): Identification and characterization of a p53 gene mutation in a human osteosarcoma cell line. Oncogene 4: 1483-1488.
50. Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker SJ, Vogelstein B, Friend S (1990): p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 10:5772-5781.
51. Miller CW, Aslo A, Tsay C, Slamon D, Ishizaki K, Toguchida J, Yamamuro T, Lampkin B, Koeffler HP (1990): Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res 50:7950-7954.
52. Chandar N, Billig B, McMaster J, Novak J (1992): Inactivation of p53 gene in human and murine osteosarcoma cells. Br J Cancer 65:208-214.
53. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B (1992): Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80-83.
54. Bogenmann E, Moghadam H, DeClerck YA, Mock A (1987): c-myc amplification and expression in newly established human osteosarcoma cell lines. Cancer Res 47:3808-3814.
55. Shew JY, Ling N, Yang XM, Fodstad O, Lee WH (1994): Antibodies detecting abnormalities of the retinoblastoma susceptibility gene product (pp110RB) in osteosarcomas and synovial sarcomas. Oncogene 4:205-214.
56. Otterson GA, Kratzke RA, Coxon A, Kim YW, Kaye FJ (1994): Absence of p16(ink4) protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 9: 3375-3378.
57. INK4. Cancer Res 54:5816-5820.